Alnylam Pharmaceuticals (LTS:0HD2) Other Gross PPE : $719 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Alnylam Pharmaceuticals Other Gross PPE?

Alnylam Pharmaceuticals's Other Gross PPE for the quarter that ended in Mar. 2024 was $719 Mil.

Alnylam Pharmaceuticals's quarterly Other Gross PPE declined from Sep. 2023 ($729 Mil) to Dec. 2023 ($590 Mil) but then increased from Dec. 2023 ($590 Mil) to Mar. 2024 ($719 Mil).

Alnylam Pharmaceuticals's annual Other Gross PPE increased from Dec. 2021 ($489 Mil) to Dec. 2022 ($574 Mil) and increased from Dec. 2022 ($574 Mil) to Dec. 2023 ($590 Mil).

Alnylam Pharmaceuticals Other Gross PPE Historical Data

The historical data trend for Alnylam Pharmaceuticals's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Other Gross PPE Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

383.58

481.01

488.81

573.88

590.27

Alnylam Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial															738.08	736.28	729.08	590.27	718.93

Alnylam Pharmaceuticals Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Alnylam Pharmaceuticals (LTS:0HD2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (LTS:0HD2) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (LTS:0HD2) Headlines

No Headlines